<DOC>
	<DOCNO>NCT00511095</DOCNO>
	<brief_summary>The purpose study evaluate safety seroprotective immune response new investigational hepatitis B virus ( HBV ) vaccine , HEPLISAV™ , subject 11-55 year old . The primary hypothesis HEPLISAV™ well tolerate .</brief_summary>
	<brief_title>Open-Label Study Safety Immunogenicity HEPLISAV™ Hepatitis B Virus Vaccine</brief_title>
	<detailed_description>Infection hepatitis B virus ( HBV ) major global health problem . Worldwide , estimate 2 billion people infect previously 350 million chronically infect . While acute HBV infection associate significant illness , risk chronic infection great importance since 5-10 % infected adult clear infection initial phase illness . About 25 % people initially clear infection later develop chronic active hepatitis . This study evaluate safety efficacy two injection HEPLISAV™ subject 11 55 year old . About 200 subject include study . Once subject consent screen , receive total two injection 28-day period , follow-up visit 8 , 12 28 week . Safety tolerability evaluate occurrence adverse event , periodic laboratory test , vital sign , local/systemic reactogenicity . Comparison : This study include control treatment ; subject receive treatment HEPLISAV™ .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Willing able give write informed consent Women childbearing potential must willing consistently use highly effective method birth control Women pregnant breastfeed Any previous HBV infection Previous vaccination ( 1 dos ) HBV vaccine Any previous autoimmune disease Are high risk recent exposure HBV , Hepatitis C Virus ( HCV ) Human Immunodeficiency Virus ( HIV ) Received blood product antibody within 3 month prior study entry Ever receive injection DNA plasmids oligonucleotides Received vaccine within 4 week prior study entry Received investigational medicinal agent within 4 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis B vaccine</keyword>
	<keyword>HBV vaccine</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>HBV</keyword>
</DOC>